An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A quick version: this piece compares two prescription peptides, sermorelin and tesamorelin, and looks at the clinical evidence doctors use to choose between them. It’s not announcing a big discovery. Instead, it’s a guide for clinicians about which drug has better research for specific uses and what to consider when picking one for a patient. Sermorelin and tesamorelin are both short chains of amino acids that act like a natural chemical your body makes to control growth hormone. In plain terms, they tell the pituitary gland (a small gland at the base of the brain) to release growth hormone. They are not the same as giving growth hormone directly; they are more like nudges that stimulate your own system to produce it. That difference matters for how they’re used and for safety. What the research shows is different for each drug. Tesamorelin has solid clinical trial evidence for one clear use: it’s FDA-approved to reduce harmful fat accumulation in the belly area of people with HIV-related lipodystrophy (a condition linked to certain HIV treatments). Those trials were done in people and showed a measurable decrease in visceral fat (the deep belly fat around organs). Sermorelin, by contrast, has a longer history as a diagnostic and performance-related agent and less robust, smaller-scale clinical trial evidence for specific medical conditions. Much of the evidence for sermorelin comes from older studies, smaller groups, or uses that aren’t FDA-approved, so its benefits in many conditions are less well established. Why this matters: if you or someone you care for is being evaluated for treatment that involves stimulating growth hormone, the difference in evidence affects outcomes and insurance. Doctors will favor tesamorelin when there’s clear, approved benefit (for HIV-related belly fat). Sermorelin might be considered in other, off-label situations where a physician thinks stimulating growth hormone could help, but that relies more on clinical judgment and individual monitoring. For most people, the question is which drug has proven, reliable results for the specific problem they’re trying to treat. Caveats and risks: both drugs influence hormone systems, so they can have side effects (joint pain, fluid retention, changes in blood sugar, injection-site reactions and the like). Because sermorelin’s evidence is thinner for many uses, there’s more uncertainty about long-term effects in those contexts. Tesamorelin is approved only for a specific HIV-related condition; using it for other purposes would be off-label and may not be supported by insurance. Neither should be used without a doctor’s evaluation, and people with certain conditions (active cancer, uncontrolled diabetes, or pituitary problems) may be at higher risk. The article is a clinical comparison, not a consumer endorsement. Bottom line: tesamorelin has stronger, condition-specific clinical evidence (and FDA approval) for reducing visceral fat in people with HIV-related lipodystrophy; sermorelin stimulates growth-hormone release too but has less robust trial data for many medical uses, so choice between them should be guided by a knowledgeable clinician.
Source: PlexusDx